Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Facebook Live with Algernon.......my comments

<< Previous

Bullboard Posts

Next >>

Comment by talisman47on Apr 05, 2021 3:50pm

168 Views

Post# 32938585

RE:RE:Facebook Live with Algernon.......my comments

In their Facebook Life telecast comments today Chris indicated that they had been looking at around $10M for Phase 3 based on approximately 1200 patients which I think is much more realistic than just saying could cost 50M. The data information indicates approx. how many patients should be in a study based on the data points. Still a lot of money !

I like the large study done on repurposing drugs that just came out today ( see my other post ) that indicates ifenprodil is identified as a strong candidate being used to fight COVID.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale